Table 1.

Group characteristics

CharacteristicVigabatrin, n = 21ACTH, n = 21p Value
* Statistically significant differences, using chi-square or t-test as required.
† In the ACTH group, the following etiologies were found: tuberous sclerosis (n = 2), hypoxic/ischemic injury (n = 2), migrational disorder (n = 2), perinatal infection (n = 2), and Aicardi syndrome (n = 1). In the vigabatrin group, symptomatic spasms were attributed to tuberous sclerosis (n = 3), migrational disorder (n = 3), Down’s syndrome (n = 2), Jacobson’s syndrome (n = 1), perinatal infection (n = 1), and hypoxic/ischemic injury (n = 1).
AED = antiepileptic drug.
Sex, n (%)
Male14 (67)9 (43)0.12
Female7 (33)12 (57)
First seizure, mo, mean ± SD3.8 ± 2.94.4 ± 2.50.45
First spasm, mo, mean ± SD4.9 ± 2.75.4 ± 2.60.55
Spasm type, n (%)
Symptomatic11 (52)9 (43)0.54
Cryptogenic6 (29)9 (43)0.33
Idiopathic4 (19)3 (14)0.68
Tuberous sclerosis3 (14)2 (10)
Other seizure type at spasm onset, n (%)6 (29)*1 (5)*0.04
EEG, pretreatment
Hypsarrhythmia12 (57)*18 (86)*0.04
Modified hypsarrhythmia9 (43)3 (14)
First AED, mo, mean ± SD5.5 ± 3.85.8 ± 2.80.78
Vigabatrin/ACTH, mo, mean ± SD8.6 ± 3.8*6.9 ± 3.3*0.05
Pretreatment development, n (%)
Normal6 (29)4 (19)0.47
Moderate delay8 (38)11 (52)0.35
Severe delay7 (33)6 (29)0.74
Follow-up, mo, mean ± SD20.6 ± 7.626.5 ± 15.80.09